PerpEquities

Equity

Vaxcyte, Inc. (PCVX) perpetual futures

PCVX perpetual futures on 2 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade PCVXUSDT.

Vaxcyte, Inc. is a clinical-stage biotechnology company developing protein-based vaccines to prevent or manage bacterial infectious diseases, led by its pneumococcal conjugate vaccine candidate VAX-24.

$55.550.0%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

venue perp mark · MEXC (PCVX/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

2/3 live markets
Venues
2
Live markets
2/3
24h volume
$109.6K
Open interest
$926.9K
Best liquidity
$205.9K
MEXC
Tightest spread
+25.1 bps
Bitget
Highest volume
$105.2K
MEXC
Settlement mix
USDT · 3/3
Perp/spot vol.
0.00x
Spot volume $106.2M
OI / float
+0.01%
Float $8.1B
Spot performance
1D-5.09%
5D-12.59%
1M-11.87%
6M+17.10%
YTD+20.05%
1Y+12.47%

Venue matrix

3 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradePCVX/USDTTrading$55.55-13.4% APR
-0.012% every 8h
+44.2 bps$205.9K14 min$105.2K$916.9KUSDT20x
BitgetTradePCVX/USDTTrading$55.390.0% APR
0.000% every 8h
+25.1 bps$102.6K$4.4K$10.1KUSDT20x
BingXTradePCVX-USDTWatchlist------USDT-

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Thin liquidity · 2 of 2 venues absorb $10k · Typical cost: +59.9 bps – +60.4 bps

Cheapest execution: Bitget · +59.6 bps

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

PCVX

Tightest spread

PCVX

Highest volume

PCVX

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-04 · next report 2027-02-23 · Updated 3h ago
All financials →

Valuation & key figures

Market cap
$8.77B
Updated 3h ago
Revenue
$0
Trailing 12 months
Revenue growth
–
FY2026 consensus
Profit margin
–
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
–
Price / sales, TTM
Peer P/E
29.2×
Similar listed perps
EV / EBITDA
-7.8×
TTM
Free cash flow
-$1.28B
Trailing 12 months
Net income
-$1.15B
Trailing 12 months
Revenue estimate
$25M
FY2026 consensus
Earnings
2027-02-23
Revenue est. $12.5M · Updated 3h ago
Dividend
–
No dividend
Revenue (TTM)$0– vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)–– vs a year agoOperating income -$1.23B
Net income (TTM)-$1.15B-74.8% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$1.28B-115.8% vs a year agoCapex $33.6M
Diluted EPS (TTM)-$8.07-63.4% vs a year agoSum of the last 4 quarters
Net cash$1.07B-34.2% vs a year agoCash + short-term investments - debt
  • Last report (2026-11-04): revenue n/a, EPS beat by 5.7%Revenue – vs $12.5M expected (–); EPS -$1.99 vs -$2.11 (+5.7%).
  • Diluted share count up 9.3% in a year149M diluted shares in Q3 '26, 136M a year earlier.
  • Net cash $1.07BCash + short-term investments $1.29B, debt incl. leases $222M; a year ago net cash $1.63B.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 189 lines Vaxcyte, Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-23
Revenue est. $12.5M · Updated 3h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-7.92$25M-6
FY 2027-6.74$68.9M+176%6
FY 2028-6.49$74.9M+9%6
FY 2029-3.13$941.4M+1,157%3
FY 20302.19$2B+107%2
Q3 2026-2.11$12.5M-4
Source: FMP · Consensus

Company events

6
2027-02-23EarningsActual - / Estimate -1.93-
2026-11-04EarningsActual -1.99 / Estimate -2.11Beat
2026-08-05EarningsActual -1.97 / Estimate -2.06Beat
2026-05-06EarningsActual -2.30 / Estimate -1.78Miss
2026-02-24EarningsActual -1.80 / Estimate -1.53Miss
2025-11-04EarningsActual -1.56 / Estimate -1.27Miss

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 21, 2026, 07:33 PM UTC
Market cap history
$8.25B-8.8%Aug 2026 – Nov 2026
$8.25B$9.46B$10.67BHigh: $10.67B · 2026-10-05Latest: $8.25B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $8.25B · 2026-11-20High: $10.67B · 2026-10-05Low: $8.25B · 2026-11-20

Not comparable with the headline: the provider's history counts about 148.91M shares, the headline 158.3M. Shown as the provider reports it.

Analyst track record

How the analysts covering PCVX have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings50167
Analysts1519
Buy / hold / sell48 / 2 / 0163 / 4 / 0
Upgrades / downgrades / initiations0 / 0 / 00 / 0 / 6
Price targets hit / missed0 / 46 (0%)4 / 134 (3%)
Avg. return after a rating (TipRanks)-43.0%-40.8%
Best / worst call-9.1% / -62.6%+60.2% / -62.6%

After buy calls on this stock: median 21-day move +3.2% vs S&P 500 +0.6% (n = 168)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Salim SyedMizuho Securities85% hit rate on this stock · 13 targets measuredBuytarget $163Oct 5, 2026
  2. Thomas ShraderBTIG53% hit rate on this stock · 15 targets measuredBuytarget $89.00Nov 4, 2026
  3. Jason GerberryBank of America Securities33% hit rate on this stock · 15 targets measuredBuyno targetNov 5, 2026

Latest ratings

DateAnalystCallTarget
Nov 5, 2026Jason GerberryBank of America SecuritiesNov 5, 2026BuyMaintained–↗
Nov 5, 2026Unknown AnalystLeerink PartnersNov 5, 2026BuyMaintained$102↗
Nov 5, 2026Tara BancroftTD CowenNov 5, 2026BuyMaintained$75.00↗
Nov 4, 2026Thomas ShraderBTIGNov 4, 2026BuyMaintained$89.00↗
Oct 18, 2026Seamus FernandezGuggenheimOct 18, 2026BuyReiterated$125↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$60.00$80.00$100$120Dec 25 · Buy 7 · Hold 1 · Sell 0Dec 25Jan 26 · Buy 7 · Hold 1 · Sell 0Feb 26 · Buy 8 · Hold 1 · Sell 0Feb 26Mar 26 · Buy 8 · Hold 1 · Sell 0Apr 26 · Buy 8 · Hold 1 · Sell 0Apr 26May 26 · Buy 8 · Hold 1 · Sell 0Jun 26 · Buy 9 · Hold 1 · Sell 0Jun 26Jul 26 · Buy 9 · Hold 1 · Sell 0Aug 26 · Buy 9 · Hold 0 · Sell 0Aug 26Sep 26 · Buy 8 · Hold 0 · Sell 0Oct 26 · Buy 12 · Hold 1 · Sell 0Oct 26Nov 26 · Buy 11 · Hold 1 · Sell 0Dec 25 · avg. target $90.33Jan 26 · avg. target $93.67Feb 26 · avg. target $112Mar 26 · avg. target $118Apr 26 · avg. target $118May 26 · avg. target $109Jun 26 · avg. target $116Jul 26 · avg. target $116Aug 26 · avg. target $121Sep 26 · avg. target $112Oct 26 · avg. target $117Nov 26 · avg. target $115Dec 25 · month-end close $46.14Jan 26 · month-end close $53.57Feb 26 · month-end close $61.74Mar 26 · month-end close $58.11Apr 26 · month-end close $57.24May 26 · month-end close $51.40Jun 26 · month-end close $58.13Jul 26 · month-end close $54.08Aug 26 · month-end close $60.74Sep 26 · month-end close $56.90Oct 26 · month-end close $62.03Nov 26 · month-end close $55.39

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 17, 2026 · 50 ratings

Frequently asked questions

Where can I trade PCVX perpetual futures?

Vaxcyte, Inc. (PCVX) perpetual futures trade on 2 crypto venues, including MEXC, Bitget. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade PCVX around the clock?

Yes. Unlike the underlying stock, PCVX perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on PCVX perpetuals?

Right now the PCVX perp funding rate is -6.7% annualized (venue median), ranging from -13.4% to 0.0% across 2 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the PCVX perp price compare to the Vaxcyte, Inc. stock?

The venue-median PCVX perp mark is $55.5 versus a reference stock price of $55.5, a basis of -0.1%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a PCVX perpetual future?

A PCVX perpetual is a derivative that tracks the price of Vaxcyte, Inc. with no expiry date. It lets you take long or short exposure to Vaxcyte, Inc. on crypto venues, around the clock.

What is PCVXUSDT perpetual?

PCVXUSDT is the symbol most crypto exchanges use for the Vaxcyte, Inc. perpetual settled in USDT (Tether). It tracks the PCVX share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

PCVX perpetuals · perpequities.comPCVX perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/pcvx-perp"><img src="https://perpequities.com/badge/pcvx-perp.svg" width="240" height="64" alt="PCVX perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of PCVX perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for PCVX — one email every Sunday.

Watchlist and alerts

Price and funding alerts for PCVX, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X